| Item type |
文献 / Documents(1) |
| 公開日 |
2020-11-18 |
| アクセス権 |
|
|
アクセス権 |
open access |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版社版DOI |
|
|
|
関連識別子 |
https://doi.org/10.2152/jmi.67.315 |
|
|
関連名称 |
10.2152/jmi.67.315 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
Clinical characteristics associated with 1-year tolvaptan efficacy in autosomal dominant polycystic kidney disease with a wide range of kidney functions |
| タイトル別表記 |
|
|
その他のタイトル |
1-year tolvaptan efficacy in ADPKD |
| 著者 |
村上, 太一
西村, 賢二
小野, 広幸
ウエタ, サヨ
柴田, 恵理子
岸, 誠司
田蒔, 昌憲
ミヤ, ケイコ
シマ, ヒサト
タシロ, マナブ
イノウエ, トモコ
カワハラ, カズヒコ
長井, 幸二郎
安部, 秀斉
ミナクチ, ジュン
土井, 俊夫
|
| 抄録 |
|
|
内容記述 |
Autosomal dominant polycystic kidney disease (ADPKD) develops into end-stage kidney disease by 65 years of age in an estimated 45%-70% of patients. Recent trials revealed that tolvaptan inhibits disease progression both in early-stage or late-stage ADPKD ; however, stratified analysis showed a difference of favorable factors correlated with tolvaptan efficacy between early-stage and late-stage ADPKD. Thus, we examined the efficacy of tolvaptan in ADPKD with a wide range of estimated glomerular filtration rates (eGFR). We enrolled 24 patients with eGFR 35.3 (28.0-65.5) ml / min / 1.73m2 and evaluated treatment effect as ΔΔeGFR (ml / min / 1.73m2 / year) or ΔΔtotal kidney volume (TKV) (% / year) that was calculated as post-treatment annual change - pre-treatment annual change. Pre ΔeGFR was significantly low in eGFR responders, defined as ΔΔeGFR > 0 ml / min / 1.73m2 / year. In eGFR responders, pre ΔeGFR, post ΔeGFR, eGFR, TKV, and proteinuria were significantly correlated with ΔΔeGFR. In TKV responders defined as ΔΔTKV > 5 % / year, we identified hypertension history, proteinuria, TKV, and post ΔTKV as significantly correlated factors with ΔΔTKV. In conclusion, pre ΔeGFR may be a predictive factor of therapeutic efficacy on kidney function. Tolvaptan may have greater efficacy in early-stage ADPKD with rapid GFR decline or with well-controlled blood pressure. |
| キーワード |
|
|
主題 |
autosomal dominant polycystic kidney disease |
| キーワード |
|
|
主題 |
tolvaptan |
| キーワード |
|
|
主題 |
theraputic efficacy |
| 書誌情報 |
en : The Journal of Medical Investigation
巻 67,
号 3-4,
p. 315-320,
発行日 2020-08
|
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
13496867 |
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
13431420 |
| 収録物ID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA11166929 |
| 出版者 |
|
|
出版者 |
Tokushima University Faculty of Medicine |
| EID |
|
|
識別子 |
381059 |
| 言語 |
|
|
言語 |
eng |
jmi_67_3-4_315.pdf (664 KB)
